联系方式：400-650-8506
CNEN
产品名称 Mirabegron - YM 178 | Betanis
产品货号 Axon 2414 CAS [223673-61-8] MF C21H24N4O2SMW 396.51 Purity: 99% Optical purity: Optically pure Soluble in DMSO Description Highly selective and orally active agonist of the human β3-adrenoceptor (EC50 value 22.4 nM) with >440 fold selectivity over β1, and β2. FDA approved therapeutic drug for the treatment of symptoms of overactive bladder such as urinary frequency, urgency, and urge incontinence. YM178 (Mirabegron) does not affect the amplitude of rhythmic bladder contractions at doses at which it reduces contraction frequency. References Certificates Categories Extra info T. Takasu et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007 May;321(2):642-7.   E. Sacco et al. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol. 2012 Dec;4(6):315-24.   N. Aizawa et al. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012 Dec;62(6):1165-73. Certificate of Analysis Material Safety Data Sheet Cardiovascular CNS A17 Adrenoceptor β3 Highly selective and orally active agonist of the human β3-adrenoceptor Chemical name (R)-2-(2-aminothiazol-4-yl)-N-(4-(2-(2-hydroxy-2-phenylethylamino)ethyl)phenyl)acetamide Parent CAS No. [223673-61-8] Order Size Unit Price Stock 10 mg €135.00 In Stock
产品价格 现货询价，电话：010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

Mirabegron - YM 178 | Betanis

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 2414

CAS [223673-61-8]

MF C21H24N4O2S
MW 396.51

  • Purity: 99%
  • Optical purity: Optically pure
  • Soluble in DMSO

Mirabegron

Description

Highly selective and orally active agonist of the human β3-adrenoceptor (EC50 value 22.4 nM) with >440 fold selectivity over β1, and β2. FDA approved therapeutic drug for the treatment of symptoms of overactive bladder such as urinary frequency, urgency, and urge incontinence. YM178 (Mirabegron) does not affect the amplitude of rhythmic bladder contractions at doses at which it reduces contraction frequency.
产品资料